TrialJournal of the American Society of Nephrology : JASN2026

Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.

Qinlan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.